论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Sun L, Chen H, Xiao Z, Guo W, Lin L
Received 12 December 2018
Accepted for publication 21 February 2019
Published 12 April 2019 Volume 2019:12 Pages 2823—2828
DOI https://doi.org/10.2147/OTT.S197923
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Abstract: Primary
clear cell carcinoma of the liver (PCCCL) is a rare and special type of primary
hepatocellular carcinoma. However, treatment methods for multiple metastatic
PCCCL are lacking. Here, we report the case of a 55-year-old male PCCCL patient
with multiple metastatic lesions who was clinically cured by sunitinib-based
systematic treatment. This patient was diagnosed with PCCCL in Liver Segment 7,
Child–Pugh A liver function, Stage A in November 16, 2009, and received radical
excision of the cancer immediately. His disease recurred with multiple
metastatic lesions in the liver and other parts of the body, including the
retroperitoneal lymph nodes, lung and bilateral adrenal nodules in June 29,
2012. The biopsy results showed that the lung mass was lung metastasis of
PCCCL. With Child–Pugh A liver function, Stage C of PCCCL was diagnosed.
Sunitinib (37.5 mg, oral, once a day [qd]) in combination with Chinese
herbal medicine (CHM) was given. The tumor size steadily reduced, and the
lesions were no longer obvious in May 21, 2014. The patient had multiple
metastases and is in complete response (CR) state until now. He is considered
as clinically cured. From the initial diagnosis of PCCCL, the survival period
reached 8 years.
Keywords: hepatocellular
carcinoma, primary clear cell carcinoma of the liver, sunitinib,
anti-angiogenesis therapy, Chinese herbal medicine